文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血浆与晶体液对血管内容量、组织灌注及组织氧合的影响:人内毒素血症模型随机对照试验

The effect of plasma versus crystalloids on intravascular volume, tissue perfusion and tissue oxygenation: a randomized controlled trial in a human endotoxemia model.
PubMed 文献 · Crit Care · 2026-02-24
一句话结论在无休克健康内毒素血症志愿者中,血浆较平衡晶体液增加血管内容量4 ml/kg并改善微循环灌注,但皮肤线粒体氧分压恢复不及晶体液。

该随机对照试验在12名健康志愿者中输注2 ng/kg脂多糖建立内毒素血症模型,6人接受10 ml/kg血浆,对照组输注10 ml/kg平衡晶体液。脂多糖引起全身炎症反应、心率与心脏指数升高、全身血管阻力下降,毛细血管再充盈时间、线粒体氧分压及灌注舌下血管均恶化。血浆输注1小时后血管内容量增加4 ml/kg,而晶体液组维持基线(p<0.01);血浆组心脏指数升高更多(p<0.05),毛细血管再充盈时间更短、灌注血管比例更高(均p<0.05);但血浆组线粒体氧分压升高幅度小于晶体液组(p<0.05)。

要点

  • 在12名健康内毒素血症志愿者中,血浆10 ml/kg输注1小时后血管内容量增加4 ml/kg,而平衡晶体液10 ml/kg组血管内容量维持在基线(p<0.01)。
  • 血浆组心脏指数升高幅度大于晶体液组(p<0.05),毛细血管再充盈时间更短、灌注血管比例更高(均p<0.05)。
  • 血浆组皮肤线粒体氧分压升高幅度小于晶体液组(p<0.05),提示血浆未能像晶体液那样恢复线粒体氧分压的下降。
  • 该试验人群为无休克的健康志愿者,结果不能直接外推至休克患者的液体复苏决策。

适用人群与场景

  • 12名健康志愿者,接受2 ng/kg脂多糖输注建立内毒素血症模型,无休克。

处置流程与药物剂量

  • 血浆组:6名参与者输注10 ml/kg血浆。
  • 对照组:输注10 ml/kg平衡晶体液。

研究设计与关键结果

  • 随机对照试验,12名健康志愿者,脂多糖2 ng/kg输注后,6人接受10 ml/kg血浆,对照组接受10 ml/kg平衡晶体液。
  • 脂多糖输注引起全身炎症反应,体温和白细胞升高,心率与心脏指数升高,全身血管阻力指数下降,毛细血管再充盈时间、线粒体氧分压和灌注舌下血管均恶化。
  • 血浆输注1小时后血管内容量增加4 ml/kg,晶体液组血管内容量维持在基线(p<0.01)。
  • 血浆组心脏指数升高幅度大于晶体液组(p<0.05)。
  • 血浆组毛细血管再充盈时间更短(p<0.05)、灌注血管比例更高(p<0.05)。
  • 血浆组线粒体氧分压升高幅度小于晶体液组(p<0.05)。

证据类型、等级与局限

  • 证据类型:随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在无休克的内毒素血症志愿者中,血浆输注较晶体液增加血管内容量和心输出量,并改善微循环组织灌注,但血浆未能像晶体液那样恢复皮肤线粒体氧分压的下降。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Fluid resuscitation is a cornerstone of shock treatment to ensure sufficient tissue perfusion. However, large volumes of crystalloids are associated with adverse outcomes and plasma has been suggested as an alternative fluid. This trial investigated the effect of plasma transfusion on circulation, tissue perfusion, and mitochondrial oxygen tension (mitoPO2) compared with balanced crystalloids in a human endotoxemia model. METHODS: Twelve healthy volunteers were subjected to 2 ng/kg lipopolysaccharide (LPS) infusion. Six participants received 10 ml/kg of plasma. In the control group, 10 ml/kg of balanced crystalloids was infused. Non-invasive cardiac index (CI), markers of the microcirculation and mitoPO2 were measured at prespecified time points. Blood volume was estimated by hemoglobin levels at each timepoint. Differences in groups over time were tested using linear mixed modeling. Wilcoxon rank-sum test was used to test the statistical difference between groups at each timepoint. RESULTS: LPS infusion resulted in a systemic inflammatory reaction with an increase in temperature and leukocytes. Heart rate and CI increased, while systemic vascular resistance (SVRI) decreased. Capillary refill time, mitoPO2 and perfused sublingual vessels all deteriorated, indicative of hyperdynamic vasodilation with redistribution of blood volume. Plasma increased intravascular volume by 4 ml/kg one hour after infusion, whereas intravascular volume remained at baseline with crystalloids (p < 0.01). Subsequently, CI increased more in the plasma group compared to the crystalloid group (p < 0.05). Tissue perfusion was improved in the plasma group, with shorter capillary refill time (p < 0.05) and a higher proportion of perfused vessels compared to the crystalloid group (p < 0.05). After fluid infusion, mitoPO2 increased less in the plasma group compared to the crystalloid group (p < 0.05). CONCLUSIONS: In healthy endotoxemic volunteers without shock, plasma infusion augmented intravascular blood volume and cardiac output, resulting in improved microcirculatory tissue perfusion compared to crystalloids. However, plasma did not restore the reduction in skin mitoPO2 as much as crystalloids. TRIAL REGISTRATION: EudraCT ID: EUCTR2020-005045-17-NL. Date of registration: 14-12-2021

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Hilderink BN, van den Brink DP, Kleinveld DJB, et al. The effect of plasma versus crystalloids on intravascular volume, tissue perfusion and tissue oxygenation: a randomized controlled trial in a human endotoxemia model. Crit Care. 2026. PMID: 41736143. doi:10.1186/s13054-026-05885-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。